Reversible autonomic dysfunction during antiviral treatment in patients with chronic hepatitis C virus infection

János Osztovits; Evelin Horváth; Judit Tax; Levente Csihi; Tamás Horváth; Levente Littvay; Tamás Tóth; Margit Abonyi; Péter László Lakatos; Márk Kollai; János Fehér; Ferenc Szalay; Hubert E. Blum

Reversible autonomic dysfunction during antiviral treatment in patients with chronic hepatitis C virus infection

János Osztovits^*
, Evelin Horváth
, Judit Tax
, Levente Csihi
, Tamás Horváth
, Levente Littvay
, Tamás Tóth
, Margit Abonyi
, Péter László Lakatos
, Márk Kollai
, János Fehér
, Ferenc Szalay
, Hubert E. Blum

^*Corresponding author for this work

Department of Political Science

Research output: Contribution to journal › Article › peer-review

Abstract (may include machine translation)

Background: The first clinical sign of chronic hepatitis C virus (HCV) infection can be one of the various extrahepatic manifestations. During antiviral treatment, symptoms of HCV-associated neuropathies usually improve, but can also worsen and lead to discontinuation of anti-HCV therapy. Recently, we have reported autonomic dysfunction in patients with HCV infection.

Objectives: In the present prospective study, we analyzed the changes of autonomic function during anti-HCV treatment.

Patients and Methods: Cardiovagal autonomic function was assessed in 22 HCV RNA-positive, treatment-naive patients by determining heart rate variability (HRV) and baroreflex sensitivity (BRS), at the beginning of treatment and 12, 24 and 48 weeks of antiviral therapy. interferon alfa-2 and ribavirin were given according to the guidelines.

Results: Both HRV and BRS time and frequency domain indices decreased after 12 weeks of therapy compared to the pre-treatment values; then the mean±SD values increased significantly by week 24 and continued to improve by week 48 of therapy-253.0±156.1 ms before therapy vs 111.6±81.9 at week 12, and 183.4±169.6 at week 24 vs 211.6±149.1 ms at week 48 for low-frequency HRV index; p<0.05 for all comparisons). These changes were independent from the presence of cryoglobulins and from virologic response.

Conclusions: The first rise followed by reversible autonomic dysfunction during antiviral therapy may be caused by the immunomodulatory actions of interferon alfa-2.

Original language	English
Pages (from-to)	114-118
Number of pages	5
Journal	Hepatitis Monthly
Volume	11
Issue number	2
State	Published - Feb 2011

Keywords

Antiviral treatment
Autonomic dysfunction
Hepatitis C virus

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3206665/pdf/hepatmon-11-114.pdf

Cite this

Osztovits, J., Horváth, E., Tax, J., Csihi, L., Horváth, T., Littvay, L., Tóth, T., Abonyi, M., Lakatos, P. L., Kollai, M., Fehér, J., Szalay, F., & Blum, H. E. (2011). Reversible autonomic dysfunction during antiviral treatment in patients with chronic hepatitis C virus infection. Hepatitis Monthly, 11(2), 114-118. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3206665/pdf/hepatmon-11-114.pdf

@article{e46a00515f7942b2bf4b12fe0072e061,

title = "Reversible autonomic dysfunction during antiviral treatment in patients with chronic hepatitis C virus infection",

abstract = "Background: The first clinical sign of chronic hepatitis C virus (HCV) infection can be one of the various extrahepatic manifestations. During antiviral treatment, symptoms of HCV-associated neuropathies usually improve, but can also worsen and lead to discontinuation of anti-HCV therapy. Recently, we have reported autonomic dysfunction in patients with HCV infection. Objectives: In the present prospective study, we analyzed the changes of autonomic function during anti-HCV treatment. Patients and Methods: Cardiovagal autonomic function was assessed in 22 HCV RNA-positive, treatment-naive patients by determining heart rate variability (HRV) and baroreflex sensitivity (BRS), at the beginning of treatment and 12, 24 and 48 weeks of antiviral therapy. interferon alfa-2 and ribavirin were given according to the guidelines. Results: Both HRV and BRS time and frequency domain indices decreased after 12 weeks of therapy compared to the pre-treatment values; then the mean±SD values increased significantly by week 24 and continued to improve by week 48 of therapy-253.0±156.1 ms before therapy vs 111.6±81.9 at week 12, and 183.4±169.6 at week 24 vs 211.6±149.1 ms at week 48 for low-frequency HRV index; p<0.05 for all comparisons). These changes were independent from the presence of cryoglobulins and from virologic response. Conclusions: The first rise followed by reversible autonomic dysfunction during antiviral therapy may be caused by the immunomodulatory actions of interferon alfa-2.",

keywords = "Antiviral treatment, Autonomic dysfunction, Hepatitis C virus",

author = "J{\'a}nos Osztovits and Evelin Horv{\'a}th and Judit Tax and Levente Csihi and Tam{\'a}s Horv{\'a}th and Levente Littvay and Tam{\'a}s T{\'o}th and Margit Abonyi and Lakatos, \{P{\'e}ter L{\'a}szl{\'o}\} and M{\'a}rk Kollai and J{\'a}nos Feh{\'e}r and Ferenc Szalay and Blum, \{Hubert E.\}",

year = "2011",

month = feb,

language = "English",

volume = "11",

pages = "114--118",

journal = "Hepatitis Monthly",

issn = "1735-143X",

publisher = "Brieflands ",

number = "2",

}

Osztovits, J, Horváth, E, Tax, J, Csihi, L, Horváth, T, Littvay, L, Tóth, T, Abonyi, M, Lakatos, PL, Kollai, M, Fehér, J, Szalay, F & Blum, HE 2011, 'Reversible autonomic dysfunction during antiviral treatment in patients with chronic hepatitis C virus infection', Hepatitis Monthly, vol. 11, no. 2, pp. 114-118. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3206665/pdf/hepatmon-11-114.pdf>

TY - JOUR

T1 - Reversible autonomic dysfunction during antiviral treatment in patients with chronic hepatitis C virus infection

AU - Osztovits, János

AU - Horváth, Evelin

AU - Tax, Judit

AU - Csihi, Levente

AU - Horváth, Tamás

AU - Littvay, Levente

AU - Tóth, Tamás

AU - Abonyi, Margit

AU - Lakatos, Péter László

AU - Kollai, Márk

AU - Fehér, János

AU - Szalay, Ferenc

AU - Blum, Hubert E.

PY - 2011/2

Y1 - 2011/2

N2 - Background: The first clinical sign of chronic hepatitis C virus (HCV) infection can be one of the various extrahepatic manifestations. During antiviral treatment, symptoms of HCV-associated neuropathies usually improve, but can also worsen and lead to discontinuation of anti-HCV therapy. Recently, we have reported autonomic dysfunction in patients with HCV infection. Objectives: In the present prospective study, we analyzed the changes of autonomic function during anti-HCV treatment. Patients and Methods: Cardiovagal autonomic function was assessed in 22 HCV RNA-positive, treatment-naive patients by determining heart rate variability (HRV) and baroreflex sensitivity (BRS), at the beginning of treatment and 12, 24 and 48 weeks of antiviral therapy. interferon alfa-2 and ribavirin were given according to the guidelines. Results: Both HRV and BRS time and frequency domain indices decreased after 12 weeks of therapy compared to the pre-treatment values; then the mean±SD values increased significantly by week 24 and continued to improve by week 48 of therapy-253.0±156.1 ms before therapy vs 111.6±81.9 at week 12, and 183.4±169.6 at week 24 vs 211.6±149.1 ms at week 48 for low-frequency HRV index; p<0.05 for all comparisons). These changes were independent from the presence of cryoglobulins and from virologic response. Conclusions: The first rise followed by reversible autonomic dysfunction during antiviral therapy may be caused by the immunomodulatory actions of interferon alfa-2.

AB - Background: The first clinical sign of chronic hepatitis C virus (HCV) infection can be one of the various extrahepatic manifestations. During antiviral treatment, symptoms of HCV-associated neuropathies usually improve, but can also worsen and lead to discontinuation of anti-HCV therapy. Recently, we have reported autonomic dysfunction in patients with HCV infection. Objectives: In the present prospective study, we analyzed the changes of autonomic function during anti-HCV treatment. Patients and Methods: Cardiovagal autonomic function was assessed in 22 HCV RNA-positive, treatment-naive patients by determining heart rate variability (HRV) and baroreflex sensitivity (BRS), at the beginning of treatment and 12, 24 and 48 weeks of antiviral therapy. interferon alfa-2 and ribavirin were given according to the guidelines. Results: Both HRV and BRS time and frequency domain indices decreased after 12 weeks of therapy compared to the pre-treatment values; then the mean±SD values increased significantly by week 24 and continued to improve by week 48 of therapy-253.0±156.1 ms before therapy vs 111.6±81.9 at week 12, and 183.4±169.6 at week 24 vs 211.6±149.1 ms at week 48 for low-frequency HRV index; p<0.05 for all comparisons). These changes were independent from the presence of cryoglobulins and from virologic response. Conclusions: The first rise followed by reversible autonomic dysfunction during antiviral therapy may be caused by the immunomodulatory actions of interferon alfa-2.

KW - Antiviral treatment

KW - Autonomic dysfunction

KW - Hepatitis C virus

UR - https://www.scopus.com/pages/publications/79952457354

M3 - Article

AN - SCOPUS:79952457354

SN - 1735-143X

VL - 11

SP - 114

EP - 118

JO - Hepatitis Monthly

JF - Hepatitis Monthly

IS - 2

ER -

Reversible autonomic dysfunction during antiviral treatment in patients with chronic hepatitis C virus infection

Abstract (may include machine translation)

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this